RÉSUMÉ
Colorectal cancer (CRC) is a highly heterogeneous disease, for which prognosis has been relegated to clinicopathologic staging for decades. There is a need to stratify subpopulations of CRC on a molecular basis to better predict outcome and assign therapies. Here we report targeted exome-sequencing of 1,321 cancer-related genes on 468 tumour specimens, which identified a subset of 17 genes that best classify CRC, with APC playing a central role in predicting overall survival. APC may assume 0, 1 or 2 truncating mutations, each with a striking differential impact on survival. Tumours lacking any APC mutation carry a worse prognosis than single APC mutation tumours; however, two APC mutation tumours with mutant KRAS and TP53 confer the poorest survival among all the subgroups examined. Our study demonstrates a prognostic role for APC and suggests that sequencing of APC may have clinical utility in the routine staging and potential therapeutic assignment for CRC.
Sujet(s)
Protéine de la polypose adénomateuse colique/génétique , Tumeurs colorectales/génétique , Mutation/génétique , Protéine de la polypose adénomateuse colique/métabolisme , Noyau de la cellule/métabolisme , Tumeurs colorectales/anatomopathologie , Gènes tumoraux , Humains , Estimation de Kaplan-Meier , Instabilité des microsatellites , Taux de mutation , Métastase tumorale , Pronostic , Modèles des risques proportionnels , Coloration et marquage , Statistique non paramétrique , Protéines de type Wingless/métabolisme , Voie de signalisation Wnt/génétique , bêta-Caténine/métabolismeRÉSUMÉ
Current consensus identifies four molecular subtypes of medulloblastoma (MB): WNT, sonic hedgehog (SHH), and groups "3/C" and "4/D". Group 4 is not well characterized, but harbors the most frequently observed chromosomal abnormality in MB, i17q, whose presence may confer a worse outcome. Recent publications have identified mutations in chromatin remodeling genes that may be overrepresented in this group, suggesting a biological role for these genes in i17q. This work seeks to explore the pathology that underlies i17q in MB. Specifically, we examine the prognostic significance of the previously-identified gene mutations in an independent set of MBs as well as to examine biological relevance of these genes and related pathways by gene expression profiling. The previously-implicated p53 signaling pathway is also examined as a putative driver of i17q tumor oncogenesis. The data show gene mutations associated with i17q tumors in previous studies (KMD6A, ZMYM3, MLL3 and GPS2) were correlated with significantly worse outcomes despite not being specific to i17q in this set. Expression of these genes did not appear to underlie the biology of the molecular variants. TP53 expression was significantly reduced in i17q/group 4 tumors; this could not be accounted for by dosage effects alone. Expression of regulators and mediators of p53 signaling were significantly altered in i17q tumors. Our findings support that chromatin remodeling gene mutations are associated with significantly worse outcomes in MB but cannot explain outcomes or pathogenesis of i17q tumors. However, expression analyses of the p53 signaling pathway shows alterations in i17q tumors that cannot be explained by dosage effects and is strongly suggestive of an oncogenic role.
Sujet(s)
Tumeurs du cervelet/diagnostic , Tumeurs du cervelet/génétique , Aberrations des chromosomes , Chromosomes humains de la paire 17 , Médulloblastome/diagnostic , Médulloblastome/génétique , Mutation , Marqueurs biologiques , Assemblage et désassemblage de la chromatine/génétique , Analyse de profil d'expression de gènes , Humains , Mâle , Pronostic , Analyse de survie , Protéine p53 suppresseur de tumeur/génétiqueRÉSUMÉ
OBJECTIVES: In recent years, research has increasingly focused on the microenvironment of classical Hodgkin lymphoma (CHL) as a predictor of treatment outcome. The focus of this study was to assess the interobserver reproducibility in interpreting macrophage-associated immunohistochemistry (IHC) for CD68 and CD163 in a retrospective cohort of 88 patients with CHL. METHODS: Staining results were correlated with clinical outcome in all patients and those with a high international prognostic score (IPS). RESULTS: The intraclass correlation (ICC) for the five hematopathologists interpreting the IHC was stronger for CD163 (0.70) than for CD68 (0.50). Using a cutoff of 25% mean macrophage reactivity and including all patients, a statistically significant difference in overall survival (OS) was seen only for CD163 (P = .0006) and not for CD68 (P = .414). Patients with a mean CD163 reactivity of 25% or more had a median OS of 71 months vs 101 months for patients with less than 25% reactivity. CD163 retained statistical significance in multivariate analysis. In patients with advanced-stage CHL with high IPS, OS was also significantly worse for those with a mean CD163 reactivity of 25% or higher. CONCLUSIONS: Our study confirms previous reports of a prognostic role of tumor-infiltrating macrophages in CHL, but only for CD163. Although most of the literature supports an increasing role of macrophage IHC as a predictor of clinical outcome, successful clinical translation will require a standardized method and reporting system.
Sujet(s)
Antigènes CD/métabolisme , Antigènes de différenciation des myélomonocytes/métabolisme , Marqueurs biologiques tumoraux/métabolisme , Maladie de Hodgkin/diagnostic , Macrophages/métabolisme , Récepteurs de surface cellulaire/métabolisme , Adulte , Survie sans rechute , Femelle , Maladie de Hodgkin/métabolisme , Maladie de Hodgkin/mortalité , Humains , Immunohistochimie , Mâle , Adulte d'âge moyen , Pronostic , Études rétrospectives , Taux de survie , Résultat thérapeutiqueRÉSUMÉ
Medulloblastoma is diagnosed histologically; treatment depends on staging and age of onset. Whereas clinical factors identify a standard- and a high-risk population, these findings cannot differentiate which standard-risk patients will relapse and die. Outcome is thought to be influenced by tumor subtype and molecular alterations. Poor prognosis has been associated with isochromosome (i)17q in some but not all studies. In most instances, molecular investigations document that i17q is not a true isochromosome but rather an isodicentric chromosome, idic(17)(p11.2), with rearrangement breakpoints mapping within the REPA/REPB region on 17p11.2. This study explores the clinical utility of testing for idic(17)(p11.2) rearrangements using an assay based on fluorescent in situ hybridization (FISH). This test was applied to 58 consecutive standard- and high-risk medulloblastomas with a 5-year minimum of clinical follow-up. The presence of i17q (ie, including cases not involving the common breakpoint), idic(17)(p11.2), and histologic subtype was correlated with clinical outcome. Overall survival (OS) and disease-free survival (DFS) were consistent with literature reports. Fourteen patients (25%) had i17q, with 10 (18%) involving the common isodicentric rearrangement. The presence of i17q was associated with a poor prognosis. OS and DFS were poor in all cases with anaplasia (4), unresectable disease (7), and metastases at presentation (10); however, patients with standard-risk tumors fared better. Of these 44 cases, tumors with idic(17)(p11.2) were associated with significantly worse patient outcomes and shorter mean DFS. FISH detection of idic(17)(p11.2) may be useful for risk stratification in standard-risk patients. The presence of this abnormal chromosome is associated with early recurrence of medulloblastoma.
Sujet(s)
Tumeurs du cervelet/génétique , Chromosomes humains de la paire 17/génétique , Réarrangement des gènes , Isochromosomes/génétique , Médulloblastome/génétique , Récidive tumorale locale/génétique , Adolescent , Adulte , Tumeurs du cervelet/mortalité , Tumeurs du cervelet/anatomopathologie , Enfant , Enfant d'âge préscolaire , Aberrations des chromosomes , Études de cohortes , Femelle , Humains , Hybridation fluorescente in situ , Nourrisson , Mâle , Médulloblastome/mortalité , Médulloblastome/anatomopathologie , Récidive tumorale locale/mortalité , Récidive tumorale locale/anatomopathologie , Pronostic , Facteurs de risque , Taux de survie , Jeune adulteRÉSUMÉ
Deletion of the dosage sensitive gene NR0B1 encoding DAX1 on chromosome Xp21.2 results in congenital adrenal hypoplasia (AHC), whereas NR0B1 duplication in 46,XY individuals leads to gonadal dysgenesis and a female phenotype. We describe a 21-year-old 46,XY female manifesting primary amenorrhea, a small immature uterus, gonadal dysgenesis, and notably absent adrenal insufficiency with a submicroscopic (257 kb) deletion upstream of NR0B1. We hypothesize that loss of regulatory sequences may have resulted in position effect up-regulation of DAX1 expression, consistent with phenotypic consequences of NR0B1 duplication. We propose that this genomic region and by extension those surrounding the dosage sensitive SRY, SOX9, SF1, and WNT-4 genes, should be examined for copy-number variation in patients with sex reversal.
Sujet(s)
Protéines de liaison à l'ADN/génétique , Troubles du développement sexuel , Délétion de gène , Récepteurs à l'acide rétinoïque/génétique , Protéines de répression/génétique , Adulte , Séquence nucléotidique , Récepteur nucléaire orphelin DAX-1 , Analyse de mutations d'ADN , Femelle , Humains , MâleRÉSUMÉ
SOX9 is a temporal and tissue-specific transcription factor involved in male sexual development and bone formation. Haploinsufficiency of SOX9 is known to cause campomelic dysplasia (CD). CD cases without SOX9 coding region mutations have been described in association with translocations that have breakpoints mapping as far as 932 kb upstream from the gene. These rearrangements suggest that position effects acting from a great distance regulate SOX9 gene expression. Studies of one such case (900 kb upstream to SOX9) have led to the delineation of a potential 2.1 kb cis-acting regulatory element 1.1 Mb upstream of SOX9, termed SOX9cre1. We investigated the role of this putative regulator in SOX9 expression. SOX9cre1 increases the activity of a minimal SOX9 promoter in reporter constructs in a dose-dependent and tissue-specific manner, consistent with an enhancer role. In silico studies identify a putative binding site within SOX9cre1 for GLI1, a downstream mediator of sonic hedgehog (SHH). Furthermore, the stimulation of primary human chondrocyte cells in culture with SHH increases endogenous SOX9 expression 3-fold. Electrophoresis mobility shift assay (EMSA) studies that demonstrate physical interactions between the GLI1 transcription factor and a putative binding site within SOX9cre1, as well as experiments in which reporter constructs are co-transfected with GLI1, suggest a direct interaction between GLI1 and SOX9cre1. GLI1-SOX9cre1 interactions are verified in chromatin immunoprecipitation experiments. These data support a direct molecular link between the Hh signaling pathway and SOX9 regulation, wherein SHH stimulates SOX9 through its mediator GLI1, and are consistent with a mechanism of SOX9 regulation through distal chromatin interactions.
Sujet(s)
Protéines Hedgehog/génétique , Protéines HMG/génétique , Facteurs de transcription/génétique , Séquence nucléotidique , Sites de fixation , Os et tissu osseux/malformations , Lignée cellulaire , Chondrocytes/cytologie , Chondrocytes/métabolisme , Immunoprécipitation de la chromatine , ADN/génétique , ADN/métabolisme , Troubles du développement sexuel , Éléments activateurs (génétique) , Régulation de l'expression des gènes , Gènes régulateurs , Gènes rapporteurs , Cellules HeLa , Humains , Techniques in vitro , Mâle , Facteur de transcription SOX-9 , Différenciation sexuelle/génétique , Facteurs de transcription/métabolisme , Protéine à doigt de zinc GLI1RÉSUMÉ
Cornelia de Lange syndrome (CdLS) is a multisystem congenital anomaly disorder characterized by prenatal and postnatal growth retardation, developmental delay, distinctive facial dysmorphism, limb malformations, and multiple organ defects. Mutations in the NIPBL gene have been discovered recently as a major etiology for this syndrome, and were detected in 27-56% of patients. Two groups have found significant differences in the severity or penetrance of some phenotypes between mutation positive and mutation negative patients. Different clinical features have also been described among patients with missense versus truncating mutations. In this study, we identified 13 NIPBL mutations in 28 unrelated Polish CdLS patients (46.4%), 11 were novel. Mutation positive patients were more severely affected in comparison to mutation negative individuals with respect to weight, height, and mean head circumference at birth, facial dysmorphism and speech impairment. Analyses of combined data from this and the two previous studies revealed that the degree of growth, developmental delay and limb defects showed significant differences between patients with and without mutations and between patients with missense and truncating mutations, whereas only a portion of these features differed significantly in any individual study. Furthermore, bioinformatic analyses of the NIPBL protein revealed several novel domains, which may give further clues about potential functions of this protein.
Sujet(s)
Syndrome de Cornelia de Lange/génétique , Mutation , Protéines/génétique , Adolescent , Adulte , Séquence d'acides aminés , Séquence nucléotidique , Protéines du cycle cellulaire , Enfant , Enfant d'âge préscolaire , ADN/génétique , Syndrome de Cornelia de Lange/anatomopathologie , Femelle , Génotype , Humains , Mâle , Données de séquences moléculaires , Mutation faux-sens , Pedigree , Phénotype , Pologne , Protéines/composition chimique , Délétion de séquenceRÉSUMÉ
Non-allelic homologous recombination (NAHR) between low-copy repeats (LCRs) has been implicated recently in somatic rearrangements including isochromosome i(17q), which is associated with hematologic malignancies as well as solid tumors. In hematological malignancies, the most common i(17q) breakpoint results from LCR-mediated NAHR, which creates a dicentric chromosome, idic(17)(p11.2). We report an elderly patient who presented with primary myelofibrosis (MF) with myeloid metaplasia (MMM), associated with idic(17)(p11.2) as the sole chromosomal abnormality, making this the first idic(17)(p11.2) myeloproliferative case reported in which the breakpoints are mapped to the breakpoint cluster region in proximal 17p. The rearrangement breakpoint maps to the previously defined LCR cluster, further suggesting that the genomic architecture of proximal 17p may be responsible for the formation of the majority of i(17q) cases. We describe our development of a rapid screening test using interphase FISH to detect idic(17)(p11.2), discuss the potential prognostic value of this molecular diagnostic test, and examine the relevance of LCR-mediated NAHR to common rearrangements in neoplasms.
Sujet(s)
Chromosomes humains de la paire 17/génétique , Interphase/génétique , Isochromosomes/génétique , Myélofibrose primitive/génétique , Recombinaison génétique , Sujet âgé , Sujet âgé de 80 ans ou plus , Moelle osseuse/ultrastructure , Zébrage chromosomique , Cassure de chromosome/génétique , Cartographie chromosomique , Humains , Hybridation fluorescente in situ , Mâle , Séquences répétées d'acides nucléiquesRÉSUMÉ
Campomelic dysplasia (CD) is a semilethal skeletal malformation syndrome with or without XY sex reversal. In addition to the multiple mutations found within the sex-determining region Y-related high-mobility group box gene (SOX9) on 17q24.3, several chromosome anomalies (translocations, inversions, and deletions) with breakpoints scattered over 1 Mb upstream of SOX9 have been described. Here, we present a balanced translocation, t(4;17)(q28.3;q24.3), segregating in a family with a mild acampomelic CD with Robin sequence. Both chromosome breakpoints have been identified by fluorescence in situ hybridization and have been sequenced using a somatic cell hybrid. The 17q24.3 breakpoint maps approximately 900 kb upstream of SOX9, which is within the same bacterial artificial chromosome clone as the breakpoints of two other reported patients with mild CD. We also report a prenatal identification of acampomelic CD with male-to-female sex reversal in a fetus with a de novo balanced complex karyotype, 46,XY,t(4;7;8;17)(4qter-->4p15.1::17q25.1-->17qter;7qter-->7p15.3::4p15.1-->4pter;8pter-->8q12.1::7p15.3-->7pter;17pter-->17q25.1::8q12.1-->8qter). Surprisingly, the 17q breakpoint maps approximately 1.3 Mb downstream of SOX9, making this the longest-range position effect found in the field of human genetics and the first report of a patient with CD with the chromosome breakpoint mapping 3' of SOX9. By using the Regulatory Potential score in conjunction with analysis of the rearrangement breakpoints, we identified a candidate upstream cis-regulatory element, SOX9cre1. We provide evidence that this 1.1-kb evolutionarily conserved element and the downstream breakpoint region colocalize with SOX9 in the interphase nucleus, despite being located 1.1 Mb upstream and 1.3 Mb downstream of it, respectively. The potential molecular mechanism responsible for the position effect is discussed.